D
Daniel Egle
Researcher at University of Innsbruck
Publications - 16
Citations - 884
Daniel Egle is an academic researcher from University of Innsbruck. The author has contributed to research in topics: Breast cancer & Randomized controlled trial. The author has an hindex of 7, co-authored 16 publications receiving 635 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo- controlled trial
Michael Gnant,Georg Pfeiler,Peter Dubsky,Michael Hubalek,Richard Greil,Raimund Jakesz,Viktor Wette,Marija Balic,Ferdinand Haslbauer,Elisabeth Melbinger,Vesna Bjelic-Radisic,Silvia Artner-Matuschek,Florian Fitzal,Christian Marth,Paul Sevelda,Brigitte Mlineritsch,Günther G. Steger,Diether Manfreda,Ruth Exner,Daniel Egle,Jonas Bergh,Franz Kainberger,Susan Talbot,Douglas Warner,Christian Fesl,Christian F. Singer +25 more
TL;DR: Adjuvant denosumab 60 mg twice per year reduces the risk of clinical fractures in postmenopausal women with breast cancer receiving aromatase inhibitors, and can be administered without added toxicity.
Journal ArticleDOI
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Gnant,Georg Pfeiler,Günther G. Steger,Daniel Egle,Richard Greil,Florian Fitzal,Viktor Wette,Marija Balic,Ferdinand Haslbauer,E. Melbinger-Zeinitzer,Vesna Bjelic-Radisic,Raimund Jakesz,Christian Marth,Paul Sevelda,Brigitte Mlineritsch,Ruth Exner,Christian Fesl,Sophie Frantal,Christian F. Singer,Austrian Breast +19 more
TL;DR: Results from the ABCSG-18 trial showed that use of denosumab as an adjuvant to aromatase inhibitor therapy significantly reduced clinical fractures.
Proceedings ArticleDOI
Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
Luca Gianni,Chiun-Sheng Huang,Daniel Egle,Begoña Bermejo,Claudio Zamagni,Marc Thill,Antonio Antón,Stefania Zambelli,Giampaolo Bianchini,Stefania Russo,Eva Ciruelos,Richrad Greil,Vladimir Semiglazov,Marco Colleoni,Catherine M. Kelly,Gabriella Mariani,Lucia Del Mastro,Ilaria Maffeis,Pinuccia Valagussa,Giuseppe Viale +19 more
TL;DR: The data suggest a role for immune regulation of response to chemotherapy, and support the concept that blockade of immune check-points may favor the achievement of durable response by immune mechanisms themselves, and in combination with classical chemotherapy.
Journal ArticleDOI
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial
Theodoros Foukakis,Gunter von Minckwitz,Nils-Olof Bengtsson,Yvonne Brandberg,Birgitta Wallberg,Tommy Fornander,Brigitte Mlineritsch,Sabine Schmatloch,Christian F. Singer,Günther G. Steger,Daniel Egle,Eva Karlsson,Lena M. S. Carlsson,Sibylle Loibl,Michael Untch,Mats Hellström,Hemming Johansson,Harald Anderson,Per-Uno Malmström,Michael Gnant,Richard Greil,Volker Möbus,Jonas Bergh +22 more
TL;DR: Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival.
Journal ArticleDOI
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial
Peter Dubsky,Christian F. Singer,Daniel Egle,Viktor Wette,Edgar Petru,Marija Balic,Angelika Pichler,Richard Greil,Andreas L. Petzer,Zsuzsanna Bago-Horvath,Christian Fesl,Stephanie Meek,Ralf Kronenwett,Margaretha Rudas,Michael Gnant,Martin Filipits,Austrian Breast +16 more
TL;DR: The 12-gene MS predicted RCB after treatment with neoadjuvant therapies for patients with HR-positive, HER2-negative early-stage breast cancer, which builds a strong rationale to use EndoPredict in biomarker-driven studies in the neoadedjuvant setting.